Clinical trials
Melanoma clinical trials
A serious form of skin cancer that develops in pigment-producing cells. We’re tracking 465 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04513028Recruiting
Beta-glucan with immunotherapy for melanoma immune response
This study tests whether taking beta-glucan alongside pembrolizumab changes how your immune system responds in people with stage III–IV melanoma. It may help researchers understand whether beta-glucan improves immunotherapy activity after cancer has been controlled.
Louisville, KentuckyAges 18 years+ - NCT04562129RecruitingPhase 2
IL-2 then ipilimumab followed by nivolumab for advanced melanoma
This Phase 2 trial studies a specific sequence of immune medicines for people with stage 3 or 4 melanoma that has spread or cannot be removed. It’s designed for melanoma that worsened after prior PD-1 treatment, aiming to shrink tumors and control disease.
Tampa, FloridaAges 18 years+ - NCT04598009RecruitingPhase 2
Binimetinib and imatinib for KIT-mutant advanced melanoma
This Phase 2 trial tests binimetinib plus imatinib in people with advanced melanoma that cannot be removed with surgery and that has a KIT mutation. It’s for melanoma that has gotten worse after standard treatment (or where standard treatment isn’t possible or tolerated).
La Jolla, CaliforniaAges 18 years+ - NCT04729543RecruitingPhase 1/Phase 2
TCR cell therapy for melanoma and head and neck cancer
This early-phase study tests a lab-made T-cell treatment that targets a specific tumor marker (MC2) in melanoma and head and neck cancers. It aims to see if the treatment can safely shrink tumors and control cancer after standard options have run out.
RotterdamAges 18 years+ - NCT04741997RecruitingEarly Phase 1
Adjuvant melanoma treatment guided by response to targeted drugs
This early-phase study looks at whether people with melanoma can get the “right” follow-up (extra) treatment based on how well their cancer responds after starting targeted drugs before surgery. The goal is to improve outcomes while better matching treatment to each person’s tumor response.
Tampa, FloridaAges 18 years+ - NCT05086692RecruitingPhase 1/Phase 2
Beta-only IL-2 therapy for advanced solid tumors
This Phase 1/2 study tests a beta-only version of IL-2, an immune-stimulating treatment, to shrink or control advanced or metastatic solid tumors. It’s mainly designed to check safety and to see if it can help patients by improving tumor response.
San Diego, CaliforniaAges 18 years+ - NCT05155033RecruitingPhase 2
A trial of PD-1 plus aldesleukin for melanoma or kidney cancer
This Phase 2 study tests whether combining anti–PD-1 treatment with aldesleukin can shrink or control metastatic melanoma or metastatic kidney (renal cell) cancer. It is mainly for people who have either not had anti–PD-1 before, or whose cancer did not respond to prior anti–PD-1 treatment.
Bethesda, MarylandAges 18–120 - NCT05361174RecruitingPhase 1/Phase 2
Testing an IOV-4001 infusion for advanced melanoma or lung cancer
This trial studies how well and how safely an infusion called IOV-4001 works in adults with advanced melanoma or non-small-cell lung cancer that cannot be removed with surgery. It also aims to see what side effects occur and whether the treatment can help control the cancer.
Los Angeles, CaliforniaAges 18–70 - NCT05428007RecruitingPhase 2
Sarilumab with three immunotherapy drugs for advanced melanoma
This Phase 2 trial tests whether adding sarilumab (an immune-blocking medicine) to three immunotherapy medicines can shrink unresectable, advanced melanoma that cannot be removed with surgery. It aims to improve how well the immune system controls the cancer, especially in Stage III or Stage IV disease.
Los Angeles, CaliforniaAges 18–100 - NCT05446155Recruiting
Studying test results to predict and diagnose melanoma
This study looks at diagnostic and prognostic factors in people who have suspicious pigmented skin lesions or melanoma that doctors are evaluating with surgery or tissue sampling. It may help improve how clinicians decide what the lesion is and what to expect over time.
Helsingborg, Skåne CountyAges 18 years+ - NCT05512481RecruitingPhase 2
Study combination treatment before surgery for high-risk acral melanoma
This Phase 2 trial tests three medicines given before surgery for people with high-risk acral melanoma (a skin cancer type). It aims to shrink or control the cancer earlier and see how well the treatment works and is tolerated.
Beijing, Beijing MunicipalityAges 18–75 - NCT05620290RecruitingPhase 1
MR-guided ultrasound plus radiation to help skin cancer respond
This Phase 1 study tests a new way to make radiation work better using MRI-guided focused ultrasound. It focuses on improving treatment for malignant melanoma and other skin cancers, while checking safety and how patients experience treatment.
Toronto, OntarioAges 18 years+ - NCT05629546RecruitingPhase 1
Nivolumab and relatlimab with lab-made memory NK cells
This Phase 1 study tests a new form of immune cells (NK cells) along with nivolumab and relatlimab for advanced melanoma that has worsened after prior PD-1/PD-L1 treatments. It may help your body recognize and attack melanoma cells more strongly.
St Louis, MissouriAges 18 years+ - NCT05940311Recruiting
Blood test for melanoma with BRAF V600E mutation
This trial studies a very sensitive blood test to detect melanoma-related genetic changes in people with BRAF V600E. It may help track the disease more closely and guide care in advanced or high-risk situations.
RomeAges 18 years+ - NCT05970497RecruitingPhase 1/Phase 2
KB707 trial for advanced solid tumors after other treatments
This early-stage trial tests KB707 in people with locally advanced or metastatic solid tumors that have not responded well to standard treatments. If you qualify, you may receive KB707 to see how well it can shrink tumors or control the disease.
Los Angeles, CaliforniaAges 18 years+ - NCT06284590RecruitingPhase 2
Injected immunotherapy plus pembrolizumab for resistant melanoma
This study tests a new approach for advanced melanoma that is not responding to standard immunotherapy (like pembrolizumab). It combines a targeted injection directly into the tumor (L19IL2, L19TNF, or both) with pembrolizumab. The goal is to see if this combination can shrink tumors and help the immune system fight the cancer.
New York, New YorkAges 18 years+ - NCT06488365Recruiting
Melanoma blood test using a new device (Cytophone)
This trial tests a new, non-invasive device called a liquid biopsy that looks for melanoma cells in your blood. It may help find cancer earlier without needing a needle biopsy.
Madison, WisconsinAges 18–80 - NCT06605417Recruiting
Understanding Birthmark to Melanoma Changes
This study looks at how certain birthmarks (nevi) change over time and might turn into melanoma. By studying tissue samples, researchers hope to better understand this process.
MarseilleAges Any age - NCT06605443Recruiting
Precision medicine for large/giant congenital nevus and melanoma
This trial uses a precision medicine approach for people with melanoma. It studies how volatile organic compounds (substances your body releases) might help guide treatment for stage II, III, or IV melanoma.
BarcelonaAges 18 years+ - NCT06608420Recruiting
Precision Medicine Study for Melanoma
This study looks at using precision medicine to better understand and treat melanoma. Patients with a confirmed melanoma diagnosis can join, helping doctors learn more about the disease and improve care.
Barcelona, CataloniaAges Any age - NCT06627244RecruitingPhase 2
Study of tebentafusp and radioembolization for uveal melanoma that spread to the liver
This trial tests whether combining a drug called tebentafusp with a procedure called radioembolization can help control uveal melanoma that has spread mainly to the liver. Radioembolization delivers tiny radioactive beads to the liver, and tebentafusp helps your immune system attack the cancer.
Miami, FloridaAges 18 years+ - NCT06660420RecruitingPhase 1
PRAME-targeted NK cells for advanced melanoma
This trial tests a new type of cell therapy using your own immune cells (NK cells) modified to target a protein called PRAME found on melanoma cells. It is for people whose melanoma has not responded to or has returned after standard immunotherapies.
Houston, TexasAges 18 years+ - NCT06680323Recruiting
Melanoma risk factors in children and young adults
This study looks for genetic and environmental causes of melanoma in people up to age 30. It may help researchers understand why some young people get this type of skin cancer.
DüsseldorfAges Up to 30 years - NCT06739226RecruitingPhase 1/Phase 2
Combination Immunotherapy for Advanced Melanoma
This trial tests a new combination immunotherapy for people with advanced melanoma. It aims to help those whose cancer has not been controlled by standard treatments.
Shenzhen, GuangdongAges 18–75
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for melanoma?
- Yes. Clin2 currently lists 465 recruiting melanoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a melanoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a melanoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.